Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases
收藏资源简介:
Regucalcin is a soluble protein that is principally expressed in hepatocytes. Studies of regucalcin have mainly been conducted in animals due to a lack of commercially available kits. We aimed to develop an enzyme-linked immunosorbent assay (ELISA) to quantify serum regucalcin in patients with hepatitis B virus (HBV)-related disease. High-titer monoclonal antibodies and a polyclonal antibody to regucalcin were produced, a double-antibody sandwich ELISA method was established, and serum regucalcin was determined in 47 chronic hepatitis B (CHB) patients, 91 HBV-related acute-on-chronic liver failure (HBV-ACLF) patients, and 33 healthy controls. The ELISA demonstrated an appropriate linear range, and high levels of reproducibility, sensitivity, specificity, accuracy, and stability. The median serum regucalcin concentrations in HBV-ACLF and CHB patients were 5.46 and 3.76 ng/mL, respectively (P<0.01), which were much higher than in healthy controls (1.72 ng/mL, both P<0.01). For the differentiation of CHB patients and healthy controls, the area under curve (AUC) was 0.86 with a cut-off of 2.42 ng/mL, 85.7% sensitivity, and 78.8% specificity. In contrast, the AUC of alanine aminotransferase (ALT) was lower (AUC=0.80, P=0.01). To differentiate ACLF from CHB, the AUC was 0.72 with a cut-off of 4.26 ng/mL, 77.0% sensitivity, and 61.2% specificity while the AUC of ALT was 0.41 (P=0.07). Thus, we have developed an ELISA that is suitable for measuring serum regucalcin and have shown that serum regucalcin increased with the severity of liver injury due to HBV-related diseases, such that it appears to be more useful than ALT as a marker of liver injury.
Regucalcin是一种主要在肝细胞中表达的可溶性蛋白质。由于缺乏商业化可用的检测试剂盒,目前针对Regucalcin的研究主要以动物为实验对象。本研究旨在开发一种酶联免疫吸附试验(enzyme-linked immunosorbent assay, ELISA),以定量检测乙型肝炎病毒(hepatitis B virus, HBV)相关疾病患者血清中的Regucalcin水平。本研究制备了高效价的抗Regucalcin单克隆抗体及多克隆抗体,建立了双抗体夹心ELISA法,并对47例慢性乙型肝炎(chronic hepatitis B, CHB)患者、91例HBV相关慢加急性肝衰竭(HBV-related acute-on-chronic liver failure, HBV-ACLF)患者以及33例健康对照者的血清Regucalcin水平进行了检测。该ELISA法展现出适宜的线性检测范围,以及良好的重复性、灵敏度、特异性、准确性与稳定性。HBV-ACLF患者与CHB患者的血清Regucalcin中位数浓度分别为5.46 ng/mL与3.76 ng/mL(均P<0.01),显著高于健康对照组的1.72 ng/mL(均P<0.01)。在区分CHB患者与健康对照者时,该方法的曲线下面积(area under curve, AUC)为0.86,临界值为2.42 ng/mL,灵敏度为85.7%,特异性为78.8%;相比之下,丙氨酸氨基转移酶(alanine aminotransferase, ALT)的AUC仅为0.80(P=0.01),性能低于本方法。在区分ACLF与CHB患者时,该方法的AUC为0.72,临界值为4.26 ng/mL,灵敏度为77.0%,特异性为61.2%;而ALT的AUC仅为0.41(P=0.07)。综上,本研究成功开发了适用于血清Regucalcin检测的ELISA法,且证实血清Regucalcin水平随HBV相关疾病所致肝损伤的严重程度升高,其作为肝损伤标志物的性能优于ALT。



